2025
SJR Q2
JCR Q2 · 2,8
OA
SCIE
Journal detail
Journal of Virus Eradication
- Publisher
- Elsevier Ltd
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
2055664020556659
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,621
- Quartile Q2
- H-Index 22
- Cites/doc 2,29
- Docs (3y) 109
- Cites (3y) 233
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 2,8
- 5Y JIF 3
- JCI 0,54
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Epidemiology Q2
- Immunology Q3
- Infectious Diseases Q2
- Public Health, Environmental and Occupational Health Q2
- Virology Q2
Areas
- Immunology and Microbiology
- Medicine
WoS categories
- Immunology | Infectious Diseases | Virology
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q2 | 0,621 | 2,8 | 3 | 0,54 | Q3 | 22 |
| 2024 | Q2 | Q3 | 0,574 | 2 | 2,5 | 0,51 | Q3 | 19 |
| 2023 | Q2 | Q2 | 0,818 | 3,5 | 3 | 0,53 | Q3 | 19 |
| 2022 | Q1 | Q2 | 1,017 | 5,5 | 3,2 | 0,62 | Q2 | 19 |
| 2021 | Q1 | Q2 | 1,799 | 5,1 | 3,2 | 0,6 | Q3 | 19 |
| 2020 | Q1 | Q2 | 1,053 | 3,7 | 3,1 | 0,67 | Q3 | 19 |
| 2019 | — | Q2 | — | 2,8 | — | 0,56 | Q3 | 19 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | IMMUNOLOGY | SCIE | Q3 | Q3 | 121/183 |
| 2025 | INFECTIOUS DISEASES | SCIE | Q2 | Q3 | 67/141 |
| 2025 | VIROLOGY | SCIE | Q3 | Q3 | 23/44 |
| 2024 | IMMUNOLOGY | SCIE | Q4 | Q3 | 143/183 |
| 2024 | INFECTIOUS DISEASES | SCIE | Q3 | Q3 | 91/137 |
| 2024 | VIROLOGY | SCIE | Q3 | Q3 | 27/42 |
| 2023 | IMMUNOLOGY | SCIE | Q2 | Q3 | 90/181 |
| 2023 | INFECTIOUS DISEASES | SCIE | Q2 | Q3 | 46/132 |
| 2023 | VIROLOGY | SCIE | Q2 | Q3 | 20/41 |
| 2022 | IMMUNOLOGY | SCIE | Q2 | Q3 | 57/161 |
| 2022 | INFECTIOUS DISEASES | SCIE | Q2 | Q2 | 25/96 |
| 2022 | VIROLOGY | SCIE | Q2 | Q3 | 10/36 |
| 2021 | IMMUNOLOGY | SCIE | Q2 | Q3 | 71/162 |
| 2021 | INFECTIOUS DISEASES | SCIE | Q2 | Q3 | 40/95 |
| 2021 | VIROLOGY | SCIE | Q2 | Q3 | 17/37 |
| 2020 | IMMUNOLOGY | SCIE | Q3 | Q3 | 96/162 |
| 2020 | INFECTIOUS DISEASES | SCIE | Q2 | Q3 | 44/93 |
| 2020 | VIROLOGY | SCIE | Q2 | Q3 | 18/37 |
| 2019 | IMMUNOLOGY | SCIE | Q3 | Q3 | 100/159 |
| 2019 | INFECTIOUS DISEASES | SCIE | Q2 | Q3 | 46/92 |
| 2019 | VIROLOGY | SCIE | Q3 | Q3 | 19/37 |